Sabine ZÃ¶chbauer-MÃ¼ller

List of Publications by Year
in descending order

74 papers	5,209 citations	136885 32 h-index	85498 71 g-index
78 all docs	78 docs citations	78 times ranked	7159 citing authors

#	Article	IF	Citations
1	Epigenetic Inactivation of RASSF1A in Lung and Breast Cancers and Malignant Phenotype Suppression. Journal of the National Cancer Institute, 2001, 93, 691-699.	3.0	695
2	Promoter Methylation and Silencing of the Retinoic Acid Receptor-Â Gene in Lung Carcinomas. Journal of the National Cancer Institute, 2000, 92, 1303-1307.	3.0	334
3	Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. International Journal of Cancer, 2003, 103, 153-160.	2.3	273
4	Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clinical Cancer Research, 2002, 8, 514-9.	3.2	255
5	A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis. Cancer Cell, 2013, 24, 167-181.	7.7	244
6	SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers. Molecular Cancer, 2017, 16, 1.	7.9	196
7	Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart, 2015, 101, 1874-1880.	1.2	181
8	CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood, 2015, 125, 90-101.	0.6	179
9	Molecular Pathogenesis of Lung Cancer. Annual Review of Physiology, 2002, 64, 681-708.	5.6	169
10	Genome-Wide Transcriptional Response to 5-Aza-2â€²-Deoxycytidine and Trichostatin A in Multiple Myeloma Cells. Cancer Research, 2008, 68, 44-54.	0.4	157
11	Genome-Wide miRNA Expression Profiling Identifies miR-9-3 and miR-193a as Targets for DNA Methylation in Nonâ€“Small Cell Lung Cancers. Clinical Cancer Research, 2012, 18, 1619-1629.	3.2	151
12	Aberrant DNA Methylation in Lung Cancer: Biological and Clinical Implications. Oncologist, 2002, 7, 451-457.	1.9	136
13	Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. International Journal of Cancer, 2003, 107, 612-616.	2.3	132
14	The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Annals of Oncology, 2002, 13, 965-973.	0.6	128
15	Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood, 2021, 137, 1669-1678.	0.6	123
16	Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia, 1997, 11, 639-643.	3.3	100
17	Lung cancer: From single-gene methylation to methylome profiling. Cancer and Metastasis Reviews, 2010, 29, 95-107.	2.7	99
18	Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers. Oncogene, 2003, 22, 1580-1588.	2.6	98

#	Article	IF	Citations
19	Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer. British Journal of Haematology, 2019, 186, 311-320.	1.2	82
20	Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. Breast Cancer Research and Treatment, 2007, 103, 283-291.	1.1	74
21	Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. Oncogene, 2006, 25, 959-968.	2.6	72
22	Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in highâ€risk Bâ€cell chronic lymphocytic leukemia. International Journal of Cancer, 2007, 121, 1984-1993.	2.3	67
23	Genome-wide CpG island methylation analyses in non-small cell lung cancer patients. Carcinogenesis, 2013, 34, 513-521.	1.3	67
24	DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. Cancer, 2004, 100, 2598-2606.	2.0	66
25	Molecular genetic abnormalities in the pathogenesis of human lung cancer. Pathology and Oncology Research, 2001, 7, 6-13.	0.9	65
26	DNA Methylation Profiles of Lymphoid and Hematopoietic Malignancies. Clinical Cancer Research, 2004, 10, 2928-2935.	3.2	59
27	ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. Lung Cancer, 2013, 80, 278-283.	0.9	59
28	Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. Oncogene, 2005, 24, 732-736.	2.6	54
29	NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma. Journal of Hepatology, 2006, 45, 81-89.	1.8	53
30	Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation. Oncogene, 2005, 24, 6249-6255.	2.6	49
31	Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced nonâ€“small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2008, 135, 1036-1041.	0.4	45
32	5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand. Blood, 2012, 119, 4242-4252.	0.6	41
33	c-JUN promotes BCR-ABLâ€“induced lymphoid leukemia by inhibiting methylation of the 5â€² region of Cdk6. Blood, 2011, 117, 4065-4075.	0.6	34
34	SOCS2 is part of a highly prognostic 4-gene signature in AML and promotes disease aggressiveness. Scientific Reports, 2019, 9, 9139.	1.6	34
35	Multidrug Resistance in Leukemias and its Reversal. Leukemia and Lymphoma, 1996, 23, 451-458.	0.6	32
36	Progressive up-regulation of genes encoding DNA methyltransferases in the colorectal adenoma-carcinoma sequence. Molecular Carcinogenesis, 2007, 46, 766-772.	1.3	32

#	Article	IF	Citations
37	MDR1 gene expression in primary colorectal carcinomas. British Journal of Cancer, 1993, 68, 691-694.	2.9	29
38	Epigenetic downâ€regulation of integrin Î±7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma. Journal of Pathology, 2015, 237, 203-214.	2.1	28
39	Neurological symptom burden impacts survival prognosis in patients with newly diagnosed nonâ€“small cell lung cancer brain metastases. Cancer, 2020, 126, 4341-4352.	2.0	27
40	DNA methylation transcriptionally regulates the putative tumor cell growth suppressor ZNF677 in non-small cell lung cancers. Oncotarget, 2015, 6, 394-408.	0.8	27
41	MDR1 Gene Expression in Lymphocytes of Patients with Renal Transplants. Nephron, 1995, 69, 277-280.	0.9	26
42	Fragile Histidine Triad (FHIT) Gene Abnormalities in Lung Cancer. Clinical Lung Cancer, 2000, 2, 141-145.	1.1	26
43	EVI1 promotes tumor growth via transcriptional repression of MS4A3. Journal of Hematology and Oncology, 2015, 8, 28.	6.9	25
44	Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trial. European Journal of Cancer, 1998, 34, 1977-1980.	1.3	24
45	Systemic Inflammation and Activation of Haemostasis Predict Poor Prognosis and Response to Chemotherapy in Patients with Advanced Lung Cancer. Cancers, 2020, 12, 1619.	1.7	24
46	DNA methylation of microRNAâ€coding genes in nonâ€smallâ€cell lung cancer patients. Journal of Pathology, 2018, 245, 387-398.	2.1	23
47	JunB is a gatekeeper for B-lymphoid leukemia. Oncogene, 2007, 26, 4863-4871.	2.6	22
48	Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study. Oncologist, 2020, 25, e1930-e1955.	1.9	20
49	Trimodality therapy for Pancoast tumors: T4 is not a contraindication to radical surgery. Journal of Surgical Oncology, 2017, 116, 227-235.	0.8	19
50	MDR1 RNA Expression as a Prognostic Factor in Acute Myeloid Leukemia: An Update. Leukemia and Lymphoma, 1993, 12, 91-94.	0.6	17
51	The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. ESMO Open, 2016, 1, e000066.	2.0	17
52	Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy. Lung Cancer, 2020, 148, 159-165.	0.9	17
53	Treatment of small cell lung cancer patients. Annals of Oncology, 1999, 10, 83-91.	0.6	17
54	Frequent overexpression of ErbB â€“ receptor family members in brain metastases of nonâ€small cell lung cancer patients. Apmis, 2013, 121, 1144-1152.	0.9	15

#	Article	IF	Citations
55	Subclinical involvement of the liver is associated with prognosis in treatment naÃ¯ve cancer patients. Oncotarget, 2017, 8, 81250-81260.	0.8	15
56	The impact of <scp>COVID</scp>â€19 on cancer care of outpatients with low socioeconomic status. International Journal of Cancer, 2022, 151, 77-82.	2.3	15
57	Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation. Frontiers in Oncology, 2020, 10, 593852.	1.3	14
58	Prognostic assessment in patients with newly diagnosed small cell lung cancer brain metastases: results from a real-life cohort. Journal of Neuro-Oncology, 2019, 145, 85-95.	1.4	13
59	Gamma Knife Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy or Targeted Therapy. Cancers, 2020, 12, 3668.	1.7	13
60	MDR1 Gene Expression in Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 1994, 13, 333-338.	0.6	11
61	Lung transplantation in patients with incidental early stage lung cancerâ€"institutional experience of a high volume center. Clinical Transplantation, 2016, 30, 912-917.	0.8	11
62	Dexverapamil as resistance modifier in acute myeloid leukaemia. Journal of Cancer Research and Clinical Oncology, 1995, 121, R21-R24.	1.2	9
63	Pre-radiosurgery leucocyte ratios and modified glasgow prognostic score predict survival in non-small cell lung cancer brain metastases patients. Journal of Neuro-Oncology, 2021, 151, 257-265.	1.4	9
64	Neutrophil-to-Lymphocyte Ratio Is Superior to Other Leukocyte-Based Ratios as a Prognostic Predictor in Nonâ€"Small Cell Lung Cancer Patients with Radiosurgically Treated Brain Metastases Under Immunotherapy or Targeted Therapy. World Neurosurgery, 2021, 151, e324-e331.	0.7	9
65	Management of malignant pleural mesotheliomaâ€"partÂ2: therapeutic approaches. Wiener Klinische Wochenschrift, 2016, 128, 618-626.	1.0	8
66	Future developments in the treatment of lung cancer. Lung Cancer, 2002, 38, 81-85.	0.9	6
67	Lung Cancer in Austria. Journal of Thoracic Oncology, 2021, 16, 725-733.	0.5	5
68	MDR1 RNA transcripts do not indicate long-term prognosis in colorectal carcinomas. European Journal of Cancer, 1997, 33, 1516-1518.	1.3	4
69	Biochip-Based Detection of KRAS Mutation in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2011, 12, 8530-8538.	1.8	4
70	Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field. ESMO Open, 2020, 5, e000880.	2.0	4
71	Influence of temporal muscle thickness on the outcome of radiosurgically treated patients with brain metastases from nonâ€"small cell lung cancer. Journal of Neurosurgery, 2022, 137, 999-1005.	0.9	4
72	Gender differences in molecularâ€guided therapy recommendations for metastatic malignant mesothelioma. Thoracic Cancer, 2020, 11, 1979-1988.	0.8	3

#	Article	IF	Citations
73	Adjuvant and Induction Chemotherapies in Non-Small-Cell Lung Cancer. Oncology Research and Treatment, 1996, 19, 221-225.	0.8	0
74	Next Generation Sequencing Identifies DNA Methylation Patterns Indicative of Disease Progression in Ph+ CML. Blood, 2014, 124, 4526-4526.	0.6	0